New ASCO/SITC Guidance Addresses Shortcomings of Immuno-Oncology Trial Reporting

The recommendations on Trial Reporting in Immuno-Oncology aim to enchance understanding of efficacy and toxicity outcomes in immuno-oncology trials.

Source: CancerNetwork - November 13, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news